Analysts Set Sanofi (NASDAQ:SNY) Target Price at $57.50

Sanofi (NASDAQ:SNY - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the four analysts that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $57.50.

SNY has been the subject of several research analyst reports. StockNews.com upgraded shares of Sanofi from a "buy" rating to a "strong-buy" rating in a report on Wednesday. Argus raised their target price on Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, July 26th. Finally, Citigroup raised Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Atria Investments Inc raised its holdings in Sanofi by 0.7% in the third quarter. Atria Investments Inc now owns 107,296 shares of the company's stock worth $6,183,000 after buying an additional 701 shares during the last quarter. Assetmark Inc. raised its holdings in Sanofi by 9.8% in the 3rd quarter. Assetmark Inc. now owns 109,375 shares of the company's stock worth $6,303,000 after acquiring an additional 9,787 shares during the last quarter. Verdence Capital Advisors LLC lifted its position in Sanofi by 2.6% in the 3rd quarter. Verdence Capital Advisors LLC now owns 30,523 shares of the company's stock valued at $1,759,000 after acquiring an additional 764 shares in the last quarter. Sittner & Nelson LLC boosted its stake in Sanofi by 566.7% during the 3rd quarter. Sittner & Nelson LLC now owns 2,000 shares of the company's stock valued at $115,000 after purchasing an additional 1,700 shares during the last quarter. Finally, Concurrent Investment Advisors LLC increased its holdings in shares of Sanofi by 5.4% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 36,973 shares of the company's stock worth $2,131,000 after purchasing an additional 1,883 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company's stock.

Sanofi Trading Up 0.7 %

Shares of SNY stock traded up $0.39 during trading hours on Friday, reaching $53.27. The company's stock had a trading volume of 1,381,542 shares, compared to its average volume of 2,109,692. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a one year low of $45.00 and a one year high of $58.97. The stock has a market capitalization of $135.19 billion, a P/E ratio of 27.18, a P/E/G ratio of 1.35 and a beta of 0.61. The firm's fifty day simple moving average is $55.92 and its 200 day simple moving average is $52.05.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion for the quarter, compared to analysts' expectations of $16.59 billion. During the same quarter in the previous year, the business posted $2.55 earnings per share. The firm's revenue for the quarter was up 12.3% compared to the same quarter last year. Equities research analysts expect that Sanofi will post 4.27 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.